{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":7,"podcast":3,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06662786\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"OrigAMI-2","nct_id":"NCT06662786","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=origami-2-nct06662786. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OrigAMI-2","arms":[{"description":"Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \\[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\\] or FOLFIRI \\[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.","label":"Arm A: Amivantamab in Combination With Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.","label":"Arm B: Cetuximab in Combination With Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-01-20","type":"ESTIMATED"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":1000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Amivantamab","otherNames":["JNJ-61186372"],"type":"BIOLOGICAL"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"BIOLOGICAL"},{"name":"5-fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Leucovorin calcium/Levoleucovorin","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Irinotecan Hydrochloride","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-12-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to 4 years and 2 months"}],"references":[],"start_date":{"date":"2024-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT06662786"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/origami-2-nct06662786"}